LTA4H and pulmonary arterial hypertension: To verify the efficacy of the LTA4H inhibitor Bestatin (Ubenimex), a multi-center, double-blind Phase 2 trial (LIBERTY clinical trial, NCT02664558) was conducted in the United States in 2016, enrolling 61 patients with PAH, but unfortunately, its efficacy could not be proven.